Rhelion Life Sciences Corp. RHEL
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -83.41% | -52.82% | 21.20% | 33.58% | 46.85% |
| Total Depreciation and Amortization | -44.53% | -54.42% | -65.57% | -50.47% | -33.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 487.70% | 424.64% | -37.79% | -68.01% | -80.78% |
| Change in Net Operating Assets | -41.62% | -51.69% | -43.56% | 1,991.30% | 35.53% |
| Cash from Operations | -84.02% | -62.52% | -42.71% | 64.69% | 40.51% |
| Capital Expenditure | 96.31% | 73.77% | 75.92% | 72.72% | 79.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,776.76% | -18,802.38% | -6,039.17% | -6,301.28% | -1,992.31% |
| Cash from Investing | -1,240.55% | -132.09% | -65.99% | -17.69% | 59.49% |
| Total Debt Issued | -11.19% | -99.21% | -63.44% | -95.04% | -95.04% |
| Total Debt Repaid | 81.78% | -464.54% | -189.34% | -214.99% | -247.98% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 84.07% | -271.73% | -259.10% | -379.36% | -397.95% |
| Foreign Exchange rate Adjustments | -387.53% | 82.89% | 309.07% | 535.75% | 6,514.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -230.23% | -182.81% | -84.79% | 29.85% | 22.23% |